Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis

Trial Profile

A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Navitoclax (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 14 Sep 2018 Planned End Date changed from 14 May 2021 to 11 Jun 2021.
    • 28 Aug 2018 Planned End Date changed from 8 Jul 2020 to 14 May 2021.
    • 31 Jan 2018 Planned End Date changed from 10 Apr 2020 to 8 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top